ESTRO 2024 - Abstract Book

S1815

Clinical - Lung

ESTRO 2024

Keywords: NSCLC, oligometastatic disease pattern, SABR

References:

1. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18-e28.

3130

Digital Poster

Impact of appropriate staging on radiotherapy planning for radical radiotherapy for lung cancer.

Linda Young 1 , Niamh Toland 1 , Suhail Baluch 1 , Jolyne O'Hare 1 , Cathryn Crockett 1 , Karen Tumelty 1 , Gerard M Walls 2 , Jonathan McAleese 1 , Gerard G Hanna 2,1 1 Northern Ireland Cancer Centre, Department of Clinical Oncology, Belfast, United Kingdom. 2 Queen’s University Belfast, Patrick G Johnston Centre for Cancer Research, Belfast, United Kingdom

Purpose/Objective:

Curative-intent or radical radiotherapy is given to up to 20% of patients with lung cancer. In addition to radiotherapy planning imaging, target volume definition in radical radiotherapy is highly dependent on staging investigations such as PET/CT. PET/CT imaging is recommended [1,2] for all patients planned for radical radiotherapy to determine the extent of extra-cranial disease, but they only provide a snapshot of disease extent at the time of acquisition. Thus, staging PET/CTs can become “out of date” and it is recommended that PET/CT staging occurs with 42 days of commencing radical radiotherapy [3,4]. In addition to PET/CT, brain imaging is recommended for patients with small cell lung cancer, in patients with stage II and stage III non-small cell lung cancer (NSCLC), with MR scanning recommended in stage III NSCLC [1,5]. We sought to evaluate the impact of appropriate and timely staging in patients receiving radical radiotherapy.

Material/Methods:

In a single centre study, we identified all patients referred for radical radiotherapy for the treatment of lung cancer during the calendar year 2022 on our prospectively collected institutional database. Demographic, disease specific and treatment details were collected and analysed using descriptive statistics. The impact of an “out of date” PET/CT was determined by identifying those patients who had a repeat PET/CT scan and impact this had on staging and radiotherapy target volumes. The impact of brain staging was determined by using the patients who had not yet had a brain scan by the time of their initial radiotherapy assessment and the impact that the subsequent brain imaging had on tumour staging.